Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230


In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R.

Cancer Res. 2011 Apr 15;71(8):2871-81. doi: 10.1158/0008-5472.CAN-10-0552. Epub 2011 Apr 12.


Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. Epub 2007 Sep 12.


Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.

Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A.

Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.


Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC.

J Immunother. 2012 Nov-Dec;35(9):689-701. doi: 10.1097/CJI.0b013e318270dec7.


CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

Davila ML, Kloss CC, Gunset G, Sadelain M.

PLoS One. 2013 Apr 9;8(4):e61338. doi: 10.1371/journal.pone.0061338. Print 2013.


CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.


Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Kochenderfer JN, Rosenberg SA.

Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. Review.


Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.

Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.


The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127. Epub 2014 Sep 11.


T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY.

Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8.


Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.

Du SH, Li Z, Chen C, Tan WK, Chi Z, Kwang TW, Xu XH, Wang S.

PLoS One. 2016 Sep 6;11(9):e0161820. doi: 10.1371/journal.pone.0161820. eCollection 2016.


Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.

An N, Tao Z, Li S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J.

Oncotarget. 2016 Mar 1;7(9):10638-49. doi: 10.18632/oncotarget.7079.


Versatile strategy for controlling the specificity and activity of engineered T cells.

Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. doi: 10.1073/pnas.1524193113. Epub 2016 Jan 12.


Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I.

J Immunother. 2009 Feb-Mar;32(2):169-80. doi: 10.1097/CJI.0b013e318194a6e8.


Treatment of advanced leukemia in mice with mRNA engineered T cells.

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.

Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.


Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.

Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.

Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22.


Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.

Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M.

PLoS One. 2015 Jun 25;10(6):e0130518. doi: 10.1371/journal.pone.0130518. eCollection 2015.


Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells.

Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE.

J Immunother. 2009 Apr;32(3):207-18. doi: 10.1097/CJI.0b013e318194a921.


Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC.

Blood. 2005 Feb 15;105(4):1622-31. Epub 2004 Oct 26.


Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ.

Blood. 2012 May 3;119(18):4133-41. doi: 10.1182/blood-2011-12-400044. Epub 2012 Feb 21.

Supplemental Content

Support Center